John L Sever

Summary

Affiliation: Children's National Medical Center
Country: USA

Publications

  1. ncbi Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)
    John L Sever
    Departments of Pediatrics, Obstetrics and Gynecology, Microbiology and Immunology, Children s National Medical Center, George Washington University, School of Medicine, 111 Michigan Avenue, N W, Washington, DC 20010 2970, USA
    Pharmacoepidemiol Drug Saf 11:189-202. 2002
  2. ncbi Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)
    John L Sever
    Department of Pediatrics, Obstetrics and Gynecology, The Children s National Medical Center, George Washington University, Washington, DC 20010 2970, USA
    Pharmacoepidemiol Drug Saf 13:825-40. 2004
  3. ncbi Therapeutic drug monitoring for patients with HIV infection: Children's National Medical Center, Washington DC experience
    Steven J Soldin
    Department of Pediatrics, The George Washington University School of Medicine, Washington, DC, USA
    Ther Drug Monit 26:107-9. 2004
  4. ncbi Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection
    Natella Y Rakhmanina
    Division of Infectious Disease, The George Washington University School of Medicine, Washington, DC 20010, USA
    Ther Drug Monit 29:110-7. 2007
  5. ncbi Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax
    Bruce C Tierney
    Epidemiology Program Office, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Clin Infect Dis 37:905-11. 2003

Collaborators

Detail Information

Publications5

  1. ncbi Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)
    John L Sever
    Departments of Pediatrics, Obstetrics and Gynecology, Microbiology and Immunology, Children s National Medical Center, George Washington University, School of Medicine, 111 Michigan Avenue, N W, Washington, DC 20010 2970, USA
    Pharmacoepidemiol Drug Saf 11:189-202. 2002
    ..To assess the safety of a licensed anthrax vaccine given to nearly 400,000 US military personnel, reports of adverse events (AEs) submitted to the Vaccine Adverse Event Reporting System (VAERS) were reviewed and evaluated medically...
  2. ncbi Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)
    John L Sever
    Department of Pediatrics, Obstetrics and Gynecology, The Children s National Medical Center, George Washington University, Washington, DC 20010 2970, USA
    Pharmacoepidemiol Drug Saf 13:825-40. 2004
    ..To assess the safety of a licensed anthrax vaccine (AVA) given to more than 500,000 US military personnel, through review and medical evaluation of adverse events (AEs) reported to the Vaccine Adverse Event Reporting System (VAERS)...
  3. ncbi Therapeutic drug monitoring for patients with HIV infection: Children's National Medical Center, Washington DC experience
    Steven J Soldin
    Department of Pediatrics, The George Washington University School of Medicine, Washington, DC, USA
    Ther Drug Monit 26:107-9. 2004
    ..Also discussed are the preliminary new and original data on free antiretroviral drug measurement in both plasma and saliva...
  4. ncbi Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection
    Natella Y Rakhmanina
    Division of Infectious Disease, The George Washington University School of Medicine, Washington, DC 20010, USA
    Ther Drug Monit 29:110-7. 2007
    ....
  5. ncbi Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax
    Bruce C Tierney
    Epidemiology Program Office, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Clin Infect Dis 37:905-11. 2003
    ..No SAEs were associated with anthrax vaccine. CDC will continue to monitor Program participants during the next 2 years...